Addison, Texas, Nov. 15, 2024 (GLOBE NEWSWIRE) -- MDB Capital Holdings, LLC, (NASDAQ:MDBH) ("MDB"), a public venture platform focused on launching category-leading deep technology companies, plans to host a Zoom webinar on Thursday November 21, 2024 at 4:30 p.m. Eastern Time to discuss its results for the third quarter 2024. A press release detailing these results will be issued prior to the call. Christopher Marlett, CEO and Co-Founder of MDB will lead the call and will be joined by other members of the management team to review recent developments, ongoing initiatives, anticipated milestones, as well as host a question-and-answer period. Investors can pre-register now for the Zoo
Addison, TX, Nov. 02, 2023 (GLOBE NEWSWIRE) -- MDB Capital Holdings, LLC, (NASDAQ:MDBH) ("MDB"), a public venture platform with the objective of growing the public venture marketplace and optimizing the way meaningful technologies are financed and built, will hold a conference call on Wednesday, November 15, 2023, at 4:30 p.m. Eastern Time to discuss its results for the third quarter ended September 30, 2023. A press release detailing these results will be issued prior to the call. Christopher Marlett, CEO and Co-Founder of MDB will lead the call and will be joined by other members of the management team to review recent developments, ongoing initiatives, anticipated 2024 milestone
Addison, Texas, June 20, 2024 (GLOBE NEWSWIRE) -- MDB Capital Holdings, LLC, (NASDAQ:MDBH) ("MDB Capital"), a public venture platform focused on launching category-leading deep technology companies, today announced the appointment of Daniel Torpey to its Board of Directors, effective June 17, 2024. With the addition of Torpey, the MDB Capital Board now comprises eight members. Torpey brings over 24 years of experience at Ernst & Young LLP (EY), where he currently serves as an Assurance Partner in the Forensic & Integrity Services practice. His expertise spans accounting, auditing, compliance, financial reporting, fraud detection, and corporate investigations. "Dan's breadth of kn
10-Q - MDB Capital Holdings, LLC (0001934642) (Filer)
DEF 14A - MDB Capital Holdings, LLC (0001934642) (Filer)
10-Q - MDB Capital Holdings, LLC (0001934642) (Filer)
8-K - MDB Capital Holdings, LLC (0001934642) (Filer)
8-K - MDB Capital Holdings, LLC (0001934642) (Filer)
S-8 - MDB Capital Holdings, LLC (0001934642) (Filer)
10-Q - MDB Capital Holdings, LLC (0001934642) (Filer)
10-K - MDB Capital Holdings, LLC (0001934642) (Filer)
Addison, TX, Nov. 21, 2024 (GLOBE NEWSWIRE) -- MDB Capital Holdings, LLC, (NASDAQ:MDBH) ("MDB"), a public venture platform focused on launching category-leading deep technology companies, today provides an update on operations through and subsequent to the quarter ended September 30, 2024. "Throughout the year, we continued to strengthen our operations to increase our capacity to curate and diligence deep technology ideas that we can ultimately finance and help stand up to become leaders in their technology category," said Christopher Marlett, CEO and Co-Founder of MDB. "At the same time, we deepened and broadened our relationships with our investor community by expanding our self-clearin
Monrovia, CA, Nov. 19, 2024 (GLOBE NEWSWIRE) -- Today, Invizyne Technologies, Inc., (NASDAQ:IZTC) ("Invizyne"), a leading designer of cell-free, enzyme-based biomanufacturing systems to produce commercially important molecules and chemicals for everyday life, announced it was awarded a $2 million project to enable enzyme production for cell-free biomanufacturing of sustainable aviation fuel (SAF). The project is a cost share grant from the U.S. Department of Defense's BioMADE initiative, in partnership with the University of Georgia. It is one of 17 BioMADE projects announced on October 30, 2024, to drive the scale-up and commercialization of American biomanufactured products. "The nex
Addison, Texas, Nov. 15, 2024 (GLOBE NEWSWIRE) -- MDB Capital Holdings, LLC, (NASDAQ:MDBH) ("MDB"), a public venture platform focused on launching category-leading deep technology companies, plans to host a Zoom webinar on Thursday November 21, 2024 at 4:30 p.m. Eastern Time to discuss its results for the third quarter 2024. A press release detailing these results will be issued prior to the call. Christopher Marlett, CEO and Co-Founder of MDB will lead the call and will be joined by other members of the management team to review recent developments, ongoing initiatives, anticipated milestones, as well as host a question-and-answer period. Investors can pre-register now for the Zoo
Monrovia, CA, Nov. 14, 2024 (GLOBE NEWSWIRE) -- Invizyne Technologies, Inc., a leading designer of cell-free, enzyme-based biomanufacturing systems to produce commercially important molecules and chemicals for everyday life, today announced the closing of its initial public offering of 1,875,000 shares of its common stock at a public offering price of $8.00 per share. The shares began trading on NASDAQ under the ticker symbol "IZTC" on November 13, 2024. The gross proceeds from the offering, before deducting underwriting discounts and commissions and other offering expenses, were approximately $15,000,000. The Company has granted a 45-day option to the underwriter to purchase up to 2
Monrovia, CA, Nov. 13, 2024 (GLOBE NEWSWIRE) -- Today, Invizyne Technologies, Inc., (NASDAQ:IZTC) ("Invizyne"), a leading designer of cell-free, enzyme-based biomanufacturing systems to produce commercially important molecules and chemicals for everyday life, started trading on Nasdaq. The successful initial public offering marks the next era of biomanufacturing, based on an idea pioneered by UCLA Professor Emeritus James Bowie over a decade ago – making enzymatic pathways function outside the constraints of living cells. "We were frustrated with the limitations of working with enzymatic pathways inside cells, which made us wonder whether we could get rid of the cells altogether," s
Monrovia, CA, Nov. 13, 2024 (GLOBE NEWSWIRE) -- Invizyne Technologies, Inc., a leading designer of cell-free, enzyme-based biomanufacturing systems to produce commercially important molecules and chemicals for everyday life, today announced that its common shares will begin trading on the NASDAQ today, November 13, 2024 at approximately 12:00pm EST under the ticker symbol "IZTC." About Invizyne Technologies, Inc.Invizyne Technologies, Inc. is a cell-free enzyme-based biomanufacturing technology company headquartered in Monrovia, California. Invizyne is redefining biomanufacturing by leveraging cell-free, multi-step, enzyme-based systems to efficiently transform natural or renewable resour
Monrovia, CA, Nov. 12, 2024 (GLOBE NEWSWIRE) -- Invizyne Technologies, Inc., a leading designer of cell-free, enzyme-based biomanufacturing systems to produce commercially important molecules and chemicals for everyday life, today announced it now expects its common shares will begin trading on the Nasdaq Capital Market tomorrow, November 13, 2024, under the ticker symbol "IZTC." The offering is now expected to close on November 14, 2024, subject to customary closing conditions. About Invizyne Technologies, Inc.Invizyne Technologies, Inc. is a cell-free enzyme-based biomanufacturing technology company headquartered in Monrovia, California. Invizyne is redefining biomanufacturing by levera
Monrovia, CA, Nov. 11, 2024 (GLOBE NEWSWIRE) -- Invizyne Technologies, Inc., a leading designer of cell-free, enzyme-based biomanufacturing systems to produce commercially important molecules and chemicals for everyday life, today announced the pricing of its initial public offering of 1,875,000 shares of its common stock at a public offering price of $8.00 per share for a total of $15,000,000 of gross proceeds to the Company, before deducting underwriting discounts and offering expenses (the "Offering"). In addition, the Company has granted a 45-day option to the underwriter to purchase up to 281,250 additional shares, representing 15% of the shares sold in the Offering, solely t
Record date of July 22, 2024 set for allocation preferences Closing and trading expected on NASDAQ on or before August 15 Addison, Texas, July 11, 2024 (GLOBE NEWSWIRE) -- MDB Capital Holdings, LLC, (NASDAQ:MDBH) ("MDB"), a public venture platform focused on launching category-leading deep technology companies, today announces the record date, allocation preference, and expected timeline for the proposed offering for Invizyne Technologies, Inc. In February 2024, Invizyne – a leading designer of cell-free, enzyme-based biomanufacturing systems to produce commercially important molecules and chemicals for everyday life and a subsidiary of MDB Capital Holdings – file
Transformative Innovations in MASH Diagnostics Dallas, Texas, July 09, 2024 (GLOBE NEWSWIRE) -- PatentVest, the first integrated IP intelligence strategy and law firm, recently published a whitepaper that presents strategic insights in the fields of Metabolic-Associated Steatohepatitis (MASH) biomarkers and Point of Care (PoC) kits for MASH diagnostics. This whitepaper serves as a valuable resource for stakeholders looking to navigate the complex and rapidly evolving landscape of these fields, offering guidance on capitalizing on innovation, collaboration, and IP protection to gain a competitive edge. "This rapid growing field is mainly driven by the recent Rezdiffra
Record date of July 22, 2024 set for allocation preferencesClosing and trading expected on NASDAQ on or before August 15Addison, Texas, July 11, 2024 (GLOBE NEWSWIRE) -- MDB Capital Holdings, LLC, (NASDAQ:MDBH) ("MDB"), a public venture platform focused on launching category-leading deep technology companies, today announces the record date, allocation preference, and expected timeline for the proposed offering for Invizyne Technologies, Inc.In February 2024, Invizyne – a leading designer of cell-free, enzyme-based biomanufacturing systems to produce commercially important molecules and chemicals for everyday life and a subsidiary of MDB Capital Holdings – filed its IPO registration stateme
Companies Reporting Before The Bell • Codere Online Luxembourg (NASDAQ:CDRO) is likely to report earnings for its third quarter. • Movano (NASDAQ:MOVE) is projected to report earnings for its third quarter. • Sypris Solutions (NASDAQ:SYPR) is estimated to report earnings for its third quarter. • LM Funding America (NASDAQ:LMFA) is projected to report earnings for its third quarter. • Milestone Scientific (AMEX:MLSS) is estimated to report earnings for its third quarter. • WiSA Technologies (NASDAQ:WISA) is estimated to report quarterly loss at $0.84 per share on revenue of $550 thousand. • AIM ImmunoTech (AMEX:AIM) is estimated to report quarterly loss at $0.11 per share on revenue of
Invizyne Technologies, Inc., a leading designer of enzyme-based biomanufacturing systems – and a "Big Idea" company from MDB Capital Holdings, LLC, (NASDAQ:MDBH) ("MDB") – today announced it received an additional $3.77 million grant from the Bioenergy Technologies Office (BETO) within the U.S. Department of Energy's (DOE's) Office of Energy Efficiency and Renewable Energy (EERE)."With our patented SimplePath™ technology platform, we developed a new way to make valuable chemicals from plant-based energy sources, thereby reducing the pollution associated with traditional production methods. This includes isobutanol, which is an industrial chemical with potential to significantly reduce green
Gainers TransCode Therapeutics, Inc. (NASDAQ:RNAZ) shares jumped 308% to $2.71 after the company announced pre-clinical gliblastoma results with its lead candidate, TTX-MC138. FaZe Holdings Inc. (NASDAQ:FAZE) gained 46.9% to $0.2247 after falling over 4% on Friday. Avalo Therapeutics, Inc. (NASDAQ:AVTX) shares climbed 23.5% to $0.1472 after gaining 16% on Friday. The company recently announced the sale of its assets relating to AVTX-801 (D-galactose), AVTX-802 (D-mannose) and AVTX-803 (L-fucose) on Sept. 12. Biophytis S.A. (NASDAQ:BPTS) shares gained 22.3% to $1.1250 after the company and Skyepharma announced the signature of a partnership agreement for the production of regulatory ba
Gainers MicroAlgo Inc. (NASDAQ:MLGO) shares jumped 74% to $7.02 after it unveiled a knowledge-enhanced backtracking search algorithm to boost the performance and efficiency of research institutions. Synaptogenix, Inc. (NASDAQ:SNPX) surged 28.7% to $0.3610. Lifezone Metals Limited (NYSE:LZM) gained 27.4% to $15.29. Lifezone Metals recently reported H1 loss of $16.77 per share. SeqLL Inc. (NASDAQ:SQL) gained 26% to $18.04. Heart Test Laboratories, Inc. (NASDAQ:HSCS) climbed 25.2% to $0.4680. Cemtrex, Inc. (NASDAQ:CETX) rose 21.7% to $6.86. Cheche Group Inc. (NASDAQ:CCG) gained 21.1% to $17.99 amid continued volatility following the company's business combination with Prime Impact Acqu
Gainers GSE Systems, Inc. (NASDAQ:GVP) shares rose 32.4% to $0.4090 in pre-market trading after falling over 3% on Thursday. Roadzen (NASDAQ:RDZN) shares rose 23.4% to $8.11 in pre-market trading after falling more than 40% on Thursday. FLJ Group Limited (NASDAQ:FLJ) shares gained 20.3% to $0.3669 in pre-market trading. Blue Star Foods Corp. (NASDAQ:BSFC) shares rose 17.1% to $0.37 in pre-market trading. Blue Star Foods recently announced closing of $5 million public offering. Avalo Therapeutics, Inc. (NASDAQ:AVTX) shares jumped 17% to $0.1199 in pre-market trading after falling 8% on Thursday. The company recently agreed to divest AVTX-800 series. Blue Water Biotech, Inc. (NASDAQ:BW